混合分子亚型共存在雌激素受体异质原发性乳腺癌中
Julia Foldi1,2,3, Kaitlyn Xiong4, Matthew Liu4
1Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
JCO precision oncology
|November 14, 2025
概括
雌激素受体 (ER) 异质乳腺癌显示混合的Luminal A和Luminal B亚型. 负ER区域表现出内分泌耐药性和化疗敏感性,影响患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 雌激素受体 (ER) 表达的内瘤异质性是乳腺癌的一个关键特征.
- 了解不同分子亚型在单个瘤中的共存对于治疗策略至关重要.
研究的目的:
- 为了研究ER-中间乳腺癌中ER表达的内异质性.
- 确定不同分子亚型 (Luminal A,Luminal B,HER2丰富,基底类) 在同一瘤内是否共存.
- 分析ER异质瘤中ER阴性区域的分子特征.
主要方法:
- 使用NanoString GeoMx平台和人类全转录组阿特拉斯探测器集进行数字空间分析.
- 对10种ER异质的 (10%-60%ER+) 和10种ER高 (>60%ER+) 的原发性乳腺癌进行分析.
主要成果:
- 在ER异质瘤中混合了Luminal A和Luminal B亚型;没有检测到基本类型的群体.
- 负ER区域显示了类似于Luminal B的特征,具有较低的ESR1和内分泌治疗敏感性基因表达.
- 负ER区域显示出更高的免疫相关基因表达和复发得分,表明内分泌耐药性和化疗敏感性.
结论:
- 中期乳腺癌呈现混合的Luminal A和Luminal B亚型.
- 负ER的瘤细胞群体表现出内分泌耐药性,但对化疗敏感.
- 这些发现可以解释ER异质乳腺癌的较差结果,并表明内分泌和化疗的综合益处.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...